-
Most Popular
Penny Stocks
Penny stocks trade at less than $5 per share. They are highly volatile and incredibly risky investments that can burn new and seasoned investors alike; they often serve as the playground for scam artists and market manipulators. However, while penny stocks can be halved in the blink of an eye, they can also double much more quickly than large-cap stocks. Investors interested in penny stocks should be aware of the risks and do their due diligence before making an investment. Read on to find out how to profit without getting scammed.
7 Space Exploration Stocks That Could Pioneer New Frontiers
Explore space exploration stocks with potential for significant growth as global competition in space technology increases.
3 Stocks to Buy That Could Turn Your Beer Money Into Champagne Showers
These three high-potential stocks could potentially turn a small investment into significant returns. Consider throwing in some beer money.
3 Stocks Under $15 That Could Make You a Millionaire
Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.
Other Stock Types you might be interested in
Recent Penny Stocks Articles
Is the Mullen (MULN) Stock Short Squeeze Already Over?
The cost to borrow fee for Mullen has plunged from its high of 742.53% on Jan. 23 while MULN stock demonstrates relative strength.
Cost to Borrow Mullen (MULN) Stock Falls 80% Overnight
Mullen's cost to borrow fee has fallen by 80% compared to yesterday, while short interest is elevated, sparking short squeeze speculation.
Why Is Geron (GERN) Stock Soaring 50% Today?
Late-stage clinical biopharma Geron delivered positive results for its blood cancer therapeutic, dramatically lifting GERN stock.
6 Things to Know About Atlis Motor Vehicles as AMV Stock Surges Today
Atlis Motor Vehicles (AMV) stock is on the move Wednesday despite a lack of news from the electric vehicle (EV) company.
Why Is Tenax Therapeutics (TENX) Stock On the Move Today?
Tenax Therapeutics (TENX) stock is on the move Wednesday after the company announced plans for a one-for-20 reverse stock split.
MMAT Stock Alert: Meta Materials Just Won a CES Award
Meta Materials has been honored by CES 2023 for its innovative products. Here's what this news means for MMAT stock.
MMAT Stock: What Is AST and Why Do MMTLP Investors Care?
MMTLP stock investors have still not yet received their shares of Next Bridge and have voiced their disapproval of several financial firms.
Why Lucira Health (LHDX) Stock Up 400% Today?
Today, investors in Lucida Health and LHDX stock are seeing impressive interest build as the company files an application with the FDA.
AMC Stock Alert: CEO Adam Aron Sounds Off Against ‘Twisted Conspiracy Theorists’
AMC Entertainment's CEO is clearly unafraid to court controversy. For today at least, AMC stock traders don't seem to take issue with this.
Short Squeeze Alert: Cost to Borrow Mullen (MULN) Stock Soars 8,000%
The cost to borrow for MULN stock has risen by over 8,000% recently, prompting speculation of a short squeeze.
Dear BBBY Stock Fans, Mark Your Calendars for Jan. 10
BBBY stock will rise or fall on the answers interim CEO Sue Gove gives when Bed Bath & Beyond reports November earnings on Jan. 10.
Tuesday Morning (TUEM) Stock Surges Ahead of Bankruptcy
TUEM stock still sells for a fraction of what it did before Christmas as a company known for keeping old brands alive online circles it.
Director Kent Puckett Just Sold Off Mullen (MULN) Stock
MULN stock is on the move as financial traders consider a Mullen insider's share sale as well as a delayed but crucial meeting.
Dear MULN Stock Fans, Mark Your Calendars for Jan. 19
MULN stock could avoid delisting, and even stay on the Russell 2000, but Mullen needs a lot more cash to make its promised electric vehicles.
Why Is Innovative Eyewear (LUCY) Stock Up 70% Today?
Innovative Eyewear (LUCY) stock is soaring over 70% today after the retailer of smart glasses licensed the Eddie Bauer brand.
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Gilead will try to win approval for what is now GS-1811, while Jounce develops other immunotherapy drugs. JNCE stock is soaring.
